

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM661636

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CALLIDITAS THERAPEUTICS AB		07/16/2021	Corporation: SWEDEN
RECEIVING PARTY DATA			
Name:	KREOS CAPITAL VI (UK) LIMITED		
Street Address:	25 Old Burlington Street		
City:	London		
State/Country:	UNITED KINGDOM		
Postal Code:	W1S 3AN		
Entity Type:	Limited Corporation: UNITED KINGDOM		
Name:	KREOS CAPITAL 2020 OPPORTUNITY (UK) LIMITED		
Street Address:	25 Old Burlington Street		
City:	London		
State/Country:	UNITED KINGDOM		
Postal Code:	W1S 3AN		
Entity Type:	Limited Corporation: UNITED KINGDOM		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Registration Number:	5734840	NEFECON	
Serial Number:	90775339	TARPEYO TOUCHPOINTS	
Serial Number:	88861008	TARPEYO	
Serial Number:	88861021	VALKIGO	
Serial Number:	88294772	CALLIDITAS THERAPEUTICS	
Serial Number:	87732055	CALLIDITAS	
CORRESPONDENCE DATA			
Fax Number:	9495676710		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9498527792		
Email:	ipprosecution@orrick.com, vsantos@orrick.com		
Correspondent Name:	ORRICK, HERRINGTON & SUTCLIFFE LLP		

CH \$165.00 5734840

TRADEMARK

Address Line 1: 2050 Main Street, Suite 1100
Address Line 4: IRVINE, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER: 44588-13

NAME OF SUBMITTER: Victor Santos

SIGNATURE: /Victor Santos/

DATE SIGNED: 07/21/2021

Total Attachments: 4

source=Grant_of_Security_Interest_(Trademarks)_-_Callidatas_Therapeutics_(July_2021)_4144-9125-5856_2#page1.tif

source=Grant_of_Security_Interest_(Trademarks)_-_Callidatas_Therapeutics_(July_2021)_4144-9125-5856_2#page2.tif

source=Grant_of_Security_Interest_(Trademarks)_-_Callidatas_Therapeutics_(July_2021)_4144-9125-5856_2#page3.tif

source=Grant_of_Security_Interest_(Trademarks)_-_Callidatas_Therapeutics_(July_2021)_4144-9125-5856_2#page4.tif

GRANT OF SECURITY INTEREST
(TRADEMARKS)

THIS GRANT OF SECURITY INTEREST, dated as of July 16, 2021, is executed by CALLIDITAS THERAPEUTICS AB (the "Grantor"), a company incorporated in Sweden, in favor of KREOS CAPITAL VI (UK) LIMITED, a company incorporated in England and Wales, and KREOS CAPITAL 2020 OPPORTUNITY (UK) LIMITED, a company incorporated in England and Wales, and the other lenders party to the Loan Agreement (as defined below) from time to time (each a "Lender" and collectively, the "Lenders").

A. Pursuant to that certain Agreement for the Provision of Loan Facilities of up to the Euro Equivalent of \$75,000,000, dated as of July 15, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), among (a) the Grantor, (b) each of the entities party thereto from time to time as a guarantor, and (c) the Lenders, the Lenders have agreed to extend loans and other financial accommodations to the Grantor upon the terms and subject to the conditions set forth therein.

B. The Grantor has adopted, used, and is using the trademarks more particularly described on Schedule 1-A annexed hereto and made a part hereof and has a bona fide intent to use the trademarks more particularly described on Schedule 1-B annexed hereto and made a part hereof, which trademarks are registered or subject to an application for registration in the United States Patent and Trademark Office (collectively, the "Trademarks").

C. The Grantor has entered into an Intellectual Property Security Agreement, dated as of July 16, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), in favor of the Lenders.

D. Pursuant to the Security Agreement, the Grantor has granted to each Lender a security interest in and lien on all right, title and interest of the Grantor in and to the Trademarks, and the entire goodwill of the business of the Grantor connected with and symbolized by such Trademarks, and all proceeds thereof (the "Trademark Collateral") and other Collateral (as defined in the Security Agreement), to secure the full, prompt, complete and final payment when due (whether at stated maturity, by acceleration or otherwise) and prompt performance and observance of all the Secured Obligations, as defined in the Security Agreement.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the Grantor does hereby further grant to each Lender a security interest in and lien on all right, title and interest of the Grantor in and to the Trademark Collateral to secure the full, prompt, complete and final payment when due (whether at stated maturity, by acceleration or otherwise) and prompt performance and observance of all the Secured Obligations, as defined in the Security Agreement.

The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lenders with respect to the security interest in and lien on the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

The Lenders' address is:

Kreos Capital VI (UK) Limited
Kreos Capital 2020 Opportunity (UK) Limited
25 Old Burlington Street
London W1S 3AN

[This Space Intentionally Left Blank]

IN WITNESS WHEREOF, the Grantor has caused this Grant of Security Interest to be executed as of the day and year first above written.

CALLIDITAS THERAPEUTICS AB,
a company incorporated in Sweden

By: Renee Aguiar-Lucander

Name: Renee Aguiar-Lucander

Title: CEO

SCHEDULE 1-A TO GRANT OF SECURITY INTEREST

TRADEMARKS

<u>Description</u>	<u>Registration Number</u>	<u>Registration Date</u>
NEFECON	Reg. No. 5734840	2019-04-23

SCHEDULE 1-B TO GRANT OF SECURITY INTEREST

TRADEMARK APPLICATIONS

<u>Description</u>	<u>Application Number</u>	<u>Application Date</u>
TARPEYO TOUCHPOINTS	App. No. 90775339	2021-06-15
TARPEYO	App. No. 88861008	2020-04-06
VALKIGO	App. No. 88861021	2020-04-06
CALLIDITAS THERAPEUTICS	App. No. 88294772	2019-02-08
CALLIDITAS	App. No. 87732055	2017-12-22